Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-09-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于关于百奥泰生物制药股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (China International Capital Corporation) regarding the use of part of idle raised funds by Bai'ao Tai Biopharmaceutical Co., Ltd. It references regulatory rules about raised funds management, details the fundraising amount, investment projects, and the company's board and supervisory approvals for temporarily supplementing working capital with idle raised funds. The document is not an announcement of a report publication but a formal verification opinion related to the use of raised funds. It does not contain full financial statements or quarterly results, nor is it a simple announcement or certification. It is a regulatory compliance verification related to capital use, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update (CAP) which usually covers fundraising or capital structure changes, or Audit Report (AR). The document length is under 5,000 characters, but it is substantive and not just a brief announcement. Therefore, the best classification is Regulatory Filings (RNS).
2020-09-21 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the use of part of idle raised funds to temporarily supplement working capital. It details the board and supervisory committee approvals, regulatory compliance, and opinions from independent directors and the sponsoring institution. The document focuses on the company's use of fundraising proceeds and related approvals, not on financial results or detailed financial statements. It is a regulatory announcement about capital usage rather than a financial report or earnings release. The document length is under 5,000 characters and is an announcement of a corporate action related to capital usage. Therefore, it fits best under Capital/Financing Update (CAP).
2020-09-21 Chinese
独立董事关于第一届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a board meeting matter regarding the use of idle raised funds to temporarily supplement working capital. It references compliance with relevant laws and company regulations, and it is a formal opinion rather than a full financial report or announcement of voting results. The document is short (915 characters) and focuses on governance and compliance related to board decisions. It does not contain financial statements or earnings data, nor is it a call transcript or capital update. It fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent director opinions on company management decisions.
2020-09-21 Chinese
第一届监事会第十五次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at the 15th meeting of the first Supervisory Board of 百奥泰生物制药股份有限公司. It details the meeting's attendance, compliance with relevant laws and regulations, and the approval of a proposal to use idle raised funds temporarily to supplement working capital. The document references compliance with the Shanghai Stock Exchange rules and the Company Law of China. It also mentions that the detailed announcement about the use of idle raised funds was published separately on the exchange website. The document is short (882 characters) and serves as a meeting resolution announcement rather than a full financial report or detailed capital update. It is not a full capital/financing update report but an official announcement of a board resolution related to financing. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories. The document is not a full capital/financing update (CAP) because it does not provide detailed financial data or a comprehensive update, but rather a meeting resolution summary. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-09-21 Chinese
2020年第三次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures and legality of a specific shareholders' meeting (the 2020 third extraordinary general meeting) of 百奥泰生物制药股份有限公司. It discusses the convening, attendance, voting procedures, and legality of the meeting and its resolutions. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report itself but a legal opinion related to a shareholders' meeting. This type of document is best classified under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and shareholder meetings but does not fit into other more specific categories like AGM Information or Board/Management Information, since it is a legal opinion rather than meeting materials or management announcements.
2020-09-10 Chinese
2020年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from a shareholders' meeting (股东大会决议公告) held on September 10, 2020. It details the meeting attendance, voting results on various proposals, and legal witness statements confirming the validity of the meeting and votes. There is no indication that this is a full annual or interim report, audit report, or earnings release. Instead, it is an official announcement of the voting results from a shareholders' meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2132 characters) and contains detailed voting results, not just a notice or link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is DVA with high confidence.
2020-09-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.